The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Jason H. Wasfy, MD: The Limitation of Cardiovascular Readmission Penalties
A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.
Dapagliflozin Improves Measures of Left Ventricular Function in T2DM Patients
A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.
Rivaroxaban Significantly Benefits Stroke Prevention in Real-World Setting
The Janssen therapy was significantly more beneficial for atrial fibrillation patients than warfarin.
Increased Air Pollution, Arterial Inflammation Linked to MACE
A new study reports an independent association between air pollution and arterial inflammation—and that the former could serve as a predictor to events like stroke and myocardial infarction.
Gregg C. Fonarow, MD: Comparing, Advancing SGLT-2 Inhibitors
No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.
ACC Updates Guidelines for Treating Patients with Atrial Fibrillation
The ACC, in conjunction with the AHA and Heart Rhythm Association, released their 2019 guideline for the management of patients with atrial fibrillation.
Neal Walker, MD: Investigating a Topical Treatment for Warts
There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.
Patrick Burnett, MD, PhD: Pipeline Progress of VP-102 for Molluscum Contagiosum
Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.
Gregg C. Fonarow, MD: Improving Heart Failure Care
Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?
Simon Murray, MD: Diagnosis and Treatment of Onychomycosis
Onychomycosis—fungal infection of the nail—is a common medical problem. Treatments are widely available, but relapse is common.
Larry Green, MD: Efficacy of Halobetasol & Tazarotene Lotion
In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.
Larry Green, MD: Halobetasol & Tazarotene Lotion in a Hispanic Population
Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.
Simon Murray, MD: AAD Recommendations for Acne Treatment
Recommendations for acne treatment drawn from AAD position paper and presentations.
Reaching a Future of Optimized Food Allergy Therapies
The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.
Ken Gordon, MD: Role of Placebo in the UltIMMa Trials
Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.
James Q. Del Rosso, DO: Unlocking Isotretinoin's Benefits
The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.
Improving Food Allergy Testing & Collaboration
What other specialties should become more involved in the network of care for allergic patients?
Hugh Windom, MD: Understanding Food Allergy Rates
Is the US population having allergies diagnosed correctly, and are allergies on the rise?
John Durkin, MD: Confocal Microscopy and its Benefits
Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.
Hyperhidrosis Associated with Higher Anxiety, Depression, ADD
The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.
Lidose-Isotretinoin Sustains Long-Term Acne Benefit Without Food Intake
A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.
Ken Gordon, MD: Clinical Implications of the UltIMMa Trials of Risankizumab
Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.
Melinda Gooderham, MD: Clinical Implications of the reSURFACE 2 Trial
Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.
Ken Gordon, MD: Insights on Risankizumab for Plaque Psoriasis
The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.
Dedee Murrell, MD: Results of the Believe-PV Pemphigus Vulgaris Trial
Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.
Melinda Gooderham, MD: 3-Year Results of the reSURFACE 2 Trial
This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.
Tildrakizumab Improves Psoriasis Patient Quality of Life
Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.
Patrick Burnett, MD, PhD: More Data from CAMP 1 & 2
Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.
Dedee Murrell, MD: Safety of PRN1008 for Pemphigus Vulgaris
The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.
Patrick Burnett, MD, PhD: Results of CAMP 1 & 2 in Molluscum Contagiosum
Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.